The influence of antigen targeting to sub-cellular compartments on the anti-allergic potential of a DNA vaccine

Vaccine

Volumn 31, Issue 51, 2013, Pages 6113-6121

  Weinberger, Esther E ^a   Isakovic, Almedina ^a   Scheiblhofer, Sandra ^a   Ramsauer, Christina ^a   Reiter, Katrin ^b   Hauser Kronberger, Cornelia ^b   Thalhamer, Josef ^a   Weiss, Richard ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

DNA vaccine; ER targeting; Immunotherapy; LIMP II; Type I allergy; Ubiquitination

Indexed keywords

ANTIALLERGIC AGENT; CELL ANTIGEN; DNA VACCINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; POLLEN ANTIGEN; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR FOXP3;

ALLERGY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIRCH; CD4+ CD25+ T LYMPHOCYTE; CELLULAR SECRETION; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; INTRACELLULAR SPACE; LUNG COMPLIANCE; LUNG RESISTANCE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT ALLERGY; SPLEEN CELL; TH1 CELL; TH2 CELL; VACCINATION;

20-AMINO-ACID C-TERMINAL TAIL OF LYSOSOMAL INTEGRAL MEMBRANE PROTEIN-II; AA; AHR; AIRWAY HYPERREACTIVITY; AMINO ACID; ANTIGEN PRESENTING CELL; APC; BAL; BALF; BRONCHOALVEOLAR LAVAGE; BRONCHOALVEOLAR LAVAGE FLUID; DNA VACCINE; ER-TARGETING; HUMAN TISSUE PLASMINOGEN ACTIVATOR LEADER PEPTIDE; IMMUNOTHERAPY; LIMP-II; LIMPII; SIT; SPECIFIC IMMUNOTHERAPY; T HELPER; T REGULATORY; TH; TPA; TREG; TYPE I ALLERGY; UBI; UBIQUITIN; UBIQUITINATION;

ALLERGENS; ANIMALS; ANTI-ALLERGIC AGENTS; BETULA; CYTOKINES; FEMALE; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; LUNG; MICE; MICE, INBRED BALB C; PROTEIN TRANSPORT; SPLEEN; VACCINES, DNA;

EID: 84888440879     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.005     Document Type: Article

References (51)

1. Lowe D.B., Shearer M.H., Kennedy R.C. DNA vaccines: successes and limitations in cancer and infectious disease. Journal of Cellular Biochemistry 2006, 98(May (2)):235-242.
2. Letourneau S., Im E.J., Mashishi T., Brereton C., Bridgeman A., Yang H., et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PloS One 2007, 2(10):e984.
3. Shabahang S., Li A.F., Escher A. Recent patents on immunoregulatory DNA vaccines for autoimmune diseases and allograft rejection. Recent Patents on DNA and Gene Sequences 2010, 4(June (2)):122-131.
4. Weiss R., Scheiblhofer S., Gabler M., Ferreira F., Leitner W.W., Thalhamer J. Is genetic vaccination against allergy possible?. International Archives of Allergy and Immunology 2006, 139(4):332-345.
5. Chua K.Y., Kuo I.C., Huang C.H. DNA vaccines for the prevention and treatment of allergy. Current Opinion in Allergy and Clinical Immunology 2009, 9(February (1)):50-54.
6. Ji H., Wang T.L., Chen C.H., Pai S.I., Hung C.F., Lin K.Y., et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Human Gene Therapy 1999, 10(November (17)):2727-2740.
7. Rodriguez F., Harkins S., Redwine J.M., de Pereda J.M., Whitton J.L.C.D4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. Journal of Virology 2001, 75(November (21)):10421-10430.
8. Ogata S., Fukuda M. Lysosomal targeting of Limp II membrane glycoprotein requires a novel Leu-Ile motif at a particular position in its cytoplasmic tail. The Journal of Biological Chemistry 1994, 269(February (7)):5210-5217.
9. Sandoval I.V., Arredondo J.J., Alcalde J., Gonzalez Noriega A., Vandekerckhove J., Jimenez M.A., et al. The residues Leu(Ile)475-Ile(Leu, Val, Ala)476, contained in the extended carboxyl cytoplasmic tail, are critical for targeting of the resident lysosomal membrane protein LIMP II to lysosomes. The Journal of Biological Chemistry 1994, 269(March (9)):6622-6631.
10. Weiss R., Leitner W.W., Scheiblhofer S., Chen D., Bernhaupt A., Mostbock S., et al. Genetic vaccination against malaria infection by intradermal and epidermal injections of a plasmid containing the gene encoding the Plasmodium berghei circumsporozoite protein. Infection and immunity 2000, 68(October (10)):5914-5919.
11. Weiss R., Durnberger J., Mostbock S., Scheiblhofer S., Hartl A., Breitenbach M., et al. Improvement of the immune response against plasmid DNA encoding OspC of Borrelia by an ER-targeting leader sequence. Vaccine 1999, 18(December (9-10)):815-824.
12. Johansson S., Ek M., Wahren B., Stout R., Liu M., Hallermalm K. Intracellular targeting of CEA results in Th1-type antibody responses following intradermal genetic vaccination by a needle-free jet injection device. The Scientific World Journal 2007, 7:987-999.
13. Rodriguez F., An L.L., Harkins S., Zhang J., Yokoyama M., Widera G., et al. DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. Journal of Virology 1998, 72(June (6)):5174-5181.
14. Thalhamer J., Weiss R., Scheiblhofer S. Gene Vaccines 2011, Springer, Vienna.
15. Delogu G., Howard A., Collins F.M., Morris S.L. DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infection and Immunity 2000, 68(June (6)):3097-3102.
16. Wu Y., Kipps T.J. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. Journal of Immunology 1997, 159(December (12)):6037-6043.
17. Bauer R., Scheiblhofer S., Kern K., Gruber C., Stepanoska T., Thalhamer T., et al. Generation of hypoallergenic DNA vaccines by forced ubiquitination: preventive and therapeutic effects in a mouse model of allergy. The Journal of Allergy and Clinical Immunology 2006, 118(July (1)):269-276.
18. Jacquet A., Magi M., Haumont M., Jurado M., Garcia L., Bollen A. Absence of immunoglobulin E synthesis and airway eosinophilia by vaccination with plasmid DNA encoding ProDer p 1. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 2003, 33(February (2)):218-225.
19. Hsu C.H., Chua K.Y., Tao M.H., Lai Y.L., Wu H.D., Huang S.K., et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nature Medicine 1996, 2(May (5)):540-544.
20. Hartl A., Kiesslich J., Weiss R., Bernhaupt A., Mostbock S., Scheiblhofer S., et al. Isoforms of the major allergen of birch pollen induce different immune responses after genetic immunization. International Archives of Allergy and Immunology 1999, 120(September (1)):17-29.
21. Weiss R., Hammerl P., Hartl A., Hochreiter R., Leitner W.W., Scheiblhofer S., et al. Design of protective and therapeutic DNA vaccines for the treatment of allergic diseases. Current Drug Targets Inflammation and Allergy 2005, 4(October (5)):585-597.
22. Hartl A., Weiss R., Hochreiter R., Scheiblhofer S., Thalhamer J. DNA vaccines for allergy treatment. Methods 2004, 32(March (3)):328-339.
23. Leitner W.W., Restifo N.P. DNA vaccines and apoptosis: to kill or not to kill?. The Journal of Clinical Investigation 2003, 112(July (1)):22-24.
24. Schmid D., Pypaert M., Munz C. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity 2007, 26(January (1)):79-92.
25. Petersen T.N., Brunak S., von Heijne G., Nielsen H. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nature Methods 2011, 8(10):785-786.
26. Ecker D.J., Stadel J.M., Butt T.R., Marsh J.A., Monia B.P., Powers D.A., et al. Increasing gene expression in yeast by fusion to ubiquitin. The Journal of Biological Chemistry 1989, 264(May (13)):7715-7719.
27. Hartl A., Kiesslich J., Weiss R., Bernhaupt A., Mostbock S., Scheiblhofer S., et al. Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen. The Journal of Allergy and Clinical Immunology 1999, 103(1 Pt 1):107-113.
28. Besnard A.G., Sabat R., Dumoutier L., Renauld J.C., Willart M., Lambrecht B., et al. Dual role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A. American Journal of Respiratory and Critical Care Medicine 2011, 183(May (9)):1153-1163.
29. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunology 2005, 6(November (11)):1123-1132.
30. Kirby A.C., Raynes J.G., Kaye P.M. CD11b regulates recruitment of alveolar macrophages but not pulmonary dendritic cells after pneumococcal challenge. The Journal of Infectious Diseases 2006, 193(January (2)):205-213.
31. Valenta R., Campana R., Marth K., van Hage M. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. Journal of Internal Medicine 2012, 272(August (2)):144-157.
32. Marenholz I., Kerscher T., Bauerfeind A., Esparza-Gordillo J., Nickel R., Keil T., et al. An interaction between filaggrin mutations and early food sensitization improves the prediction of childhood asthma. The Journal of Allergy and Clinical Immunology 2009, 123(April (4)):911-916.
33. Senthilselvan A., Rennie D., Chenard L., Burch L.H., Babiuk L., Schwartz D.A., et al. Association of polymorphisms of toll-like receptor 4 with a reduced prevalence of hay fever and atopy. Annals of Allergy, Asthma and Immunology: Official Publication of the American College of Allergy, Asthma, and Immunology 2008, 100(May (5)):463-468.
34. D'Vaz N., Ma Y., Dunstan J.A., Lee-Pullen T.F., Hii C., Meldrum S., et al. Neonatal protein kinase C zeta expression determines the neonatal T-Cell cytokine phenotype and predicts the development and severity of infant allergic disease. Allergy 2012, 67(December (12)):1511-1518.
35. Scheiblhofer S., Gabler M., Leitner W.W., Bauer R., Zoegg T., Ferreira F., et al. Inhibition of type I allergic responses with nanogram doses of replicon-based DNA vaccines. Allergy 2006, 61(July (7)):828-835.
36. Gabler M., Scheiblhofer S., Kern K., Leitner W.W., Stoecklinger A., Hauser-Kronberger C., et al. Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization. The Journal of Allergy and Clinical Immunology 2006, 118(September (3)):734-741.
37. Roesler E., Weiss R., Weinberger E.E., Fruehwirth A., Stoecklinger A., Mostbock S., et al. Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. The Journal of Allergy and Clinical Immunology 2009, 124(November (5)):10707e1-10707e11.
38. Fissolo N., Costa C., Nurtdinov R.N., Bustamante M.F., Llombart V., Mansilla M.J., et al. Treatment with MOG-DNA vaccines induces CD4+ CD25+ FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis. Journal of Neuroinflammation 2012, 9:139.
39. Mohr E., Cunningham A.F., Toellner K.M., Bobat S., Coughlan R.E., Bird R.A., et al. IFN-{gamma} produced by CD8 T cells induces T-bet-dependent and -independent class switching in B cells in responses to alum-precipitated protein vaccine. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(October (40)):17292-17297.
40. Serre K., Mohr E., Gaspal F., Lane P.J., Bird R., Cunningham A.F., et al. IL-4 directs both CD4 and CD8 T cells to produce Th2 cytokines in vitro, but only CD4 T cells produce these cytokines in response to alum-precipitated protein in vivo. Molecular Immunology 2010, 47(June (10)):1914-1922.
41. de la Rosa M., Rutz S., Dorninger H., Scheffold A. Interleukin-2 is essential for CD4+ CD25+ regulatory T cell function. European Journal of Immunology 2004, 34(September (9)):2480-2488.
42. Piccirillo C.A., Letterio J.J., Thornton A.M., McHugh R.S., Mamura M., Mizuhara H., et al. CD4(+) CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. The Journal of Experimental Medicine 2002, 196(July (2)):237-246.
43. Besnard A.G., Togbe D., Couillin I., Tan Z., Zheng S.G., Erard F., et al. Inflammasome-IL-1-Th17 response in allergic lung inflammation. Journal of Molecular Cell Biology 2012, 4(February (1)):3-10.
44. Cassard L., Jonsson F., Arnaud S., Daeron M. Fcgamma receptors inhibit mouse and human basophil activation. Journal of Immunology 2012, 189(September (6)):2995-3006.
45. James L.K., Shamji M.H., Walker S.M., Wilson D.R., Wachholz P.A., Francis J.N., et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. The Journal of Allergy and Clinical Immunology 2011, 127(February (2)):50916e1-50916e5.
46. Mothes N., Heinzkill M., Drachenberg K.J., Sperr W.R., Krauth M.T., Majlesi Y., et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 2003, 33(September (9)):1198-1208.
47. Vrtala S., Fohr M., Campana R., Baumgartner C., Valent P., Valenta R. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine 2011, 29(March (11)):2140-2148.
48. Wallmann J., Proell M., Stepanoska T., Hantusch B., Pali-Scholl I., Thalhamer T., et al. A mimotope gene encoding the major IgE epitope of allergen Phl p 5 for epitope-specific immunization. Immunology Letters 2009, 122(January (1)):68-75.
49. Ephrem A., Epstein A.L., Stephens G.L., Thornton A.M., Glass D., Shevach E.M. Modulation of Treg cells/T effector function by GITR signaling is context-dependent. European Journal Of Immunology 2013.
50. Albrecht M., Arnhold M., Lingner S., Mahapatra S., Bruder D., Hansen G., et al. IL-4 attenuates pulmonary epithelial cell-mediated suppression of T cell priming. PloS One 2012, 7(9):e45916.
51. Nocentini G., Riccardi C. GITR: a modulator of immune response and inflammation. Advances in Experimental Medicine and Biology 2009, 647:156-173.